In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

Analyst Andrew Berens from Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price target at ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca PLC AZN shares were unchanged Monday at £104.74, on what proved to be an all-around great trading session for the ...

The Central Drugs Standard Control Organisation (CDSCO) granted approval for its use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults ...

AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately. The new changes include increased representation of the company’s ...

Finally, TD Cowen boosted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Three equities research ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 16,142.88 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer ...